This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in HER2-directed therapies in gynecologic cancers and of treatment options based on HER2 results. A particular focus of this activity is the DESTINY-PanTumor02 study and the latest evidence regarding HER2 testing, scoring and reporting in gynecologic cancers. The microlearning design of this activity allows for a brief and focused exploration of this topic.
Course topics include:
- DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers
- HER2 testing and scoring in endometrial, cervical, ovarian cancers
- Specimen handling, scoring, reporting
- Treatment implications based on HER2 results
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Review the DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers
- Describe methods of HER2 testing and scoring in endometrial, cervical, ovarian cancers
- Discuss practical considerations around specimen handling, scoring, reporting
- Understand treatment implications for patients based on HER2 results
Faculty
Jennifer MacDonald, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic Oncology
Hollings Cancer Center, Medical University of South Carolina
Charleston, South Carolina
Sadia Sayeed MD
Assistant Professor of Pathology, Director of Cytopathology, Department of Pathology
Virginia Commonwealth University Health
Richmond, Virginia
Faculty Disclosures
All relevant financial relationships for Jennifer MacDonald have been mitigated. Sadia Sayeed has no financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of .25 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must participate in the course. CME certificates will be provided on-line.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.